Concepedia

Promoiety Selection

Promoiety Selection is the systematic decision-making process in prodrug design whereby a specific promoiety is chosen based on its chemical compatibility, bioreversible characteristics, and ability to optimize the pharmacokinetic or pharmacodynamic properties of the parent drug.

2

Publications

31

Citations

5

Authors

4

Institutions

Publications per year

2017–2026

0

Parents

Children

Publications

2

1–3 of 2

Authors

5

  1. JB
    Jonas Boström

    AstraZeneca (Sweden), Sweden

    1 publications · 21 citations

    1

    h-index

  2. HG
    Helmut Gaugitsch

    Environment Agency Austria, Austria

    1 publications · 10 citations

    1

    h-index

  3. BJ
    Bernhard Jank

    University of Vienna, Austria

    1 publications · 10 citations

    1

    h-index

  4. NF
    Niklas Falk

    AstraZeneca (Sweden), Sweden

    1 publications · 21 citations

    1

    h-index

  5. CT
    Christian Tyrchan

    AstraZeneca (Sweden), Sweden

    1 publications · 21 citations

    1

    h-index

1–5 of 5

Institutions

4

  1. Environment Agency Austria

    Vienna, Austria

    1 h-index

    1 publications

    10 citations

  2. Environment Agency

    Rotherham, United Kingdom

    1 h-index

    1 publications

    10 citations

  3. AstraZeneca (Sweden)

    Södertälje, Sweden

    1 h-index

    3 publications

    63 citations

  4. BOKU University

    Vienna, Austria

    1 h-index

    1 publications

    10 citations

  5. University of North Carolina at Charlotte

    Charlotte, United States

    1 publications

    10 citations

1–5 of 4

Venues

  1. Trends in biotechnology

    TIBTECH · 1 publications · 10 citations

    1

    h-index

  2. Drug Discovery Today

    1 publications · 21 citations

    1

    h-index

  3. Trends in Biochemical Sciences

    TIBS · 1 publications · 10 citations

1–3